Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SpinCity1 who wrote (87675)	5/23/2003 9:15:14 AM
From: SpinCity1	Respond to of 208838

DNDN Dendreon, Antigenics boosted by repoort on research (DNDN, AGEN) By Ted Griffith Shares of Dendreon and Antigenics surged in pre-market trading Friday after a published report highlighted the potential of the biotech firms' approach to combating cancer. A report in The Wall Street Journal examined the possibility of using dendritic immune system cells to fight cancer and mentioned Dendreon and Antigenics as companies working on experimental dendritic therapies. Shares of Dendreon (DNDN) surged $1.52, or 27 percent, to $7.09 and shares of Antigenics (AGEN) tacked on $1.34 to $11.95.